Zenlabs Ethica (BOM:530697) ROCE % : 11.61% (As of Dec. 2024)

View and export this data going back to 1995. Start your Free Trial

What is Zenlabs Ethica ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Zenlabs Ethica's annualized ROCE % for the quarter that ended in Dec. 2024 was 11.61%.

Zenlabs Ethica ROCE % Historical Data

The historical data trend for Zenlabs Ethica's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenlabs Ethica ROCE % Chart

Zenlabs Ethica Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

-11.11

12.15

13.53

9.01

10.13

Zenlabs Ethica Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															11.02	12.77	9.06	9.63	11.61

Zenlabs Ethica ROCE % Calculation

Zenlabs Ethica's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	13.815	/	( ( (434.93 - 294.518)	+	(402.584 - 270.212) )	/ 2 )
	=	13.815	/	( (140.412	+	132.372)	/ 2 )
	=	13.815	/	136.392
	=	10.13 %

Zenlabs Ethica's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	14.676	/	( ( (404.668 - 278.208)	+	(0 - 0) )	/ 1 )
	=	14.676	/	( ( 126.46	+	0 )	/ 1 )
	=	14.676	/	126.46
	=	11.61 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Zenlabs Ethica (BOM:530697) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Zenlabs Ethica ROCE % Related Terms

Thank you for viewing the detailed overview of Zenlabs Ethica's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenlabs Ethica Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Zenlabs Ethica Ltd (BOM:530697) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Plot No.194-195, 3rd Floor, Industrial Area, Phase-II, Ram Darbar, Chandigarh, IND, 160002

Website

https://www.zenlabsethica.com

Zenlabs Ethica Ltd is a pharmaceutical company engaged in the trading of pharmaceutical formulations. It manufactures and markets drugs which include Gastrointestinal disorders, anti-diabetics, anti-hypertensive drugs, anti-infective, soaps, and anti-Bacterial drugs, nutraceuticals, and others. In addition, The company offers more than 600 products across therapeutic segments.

Zenlabs Ethica Headlines

No Headlines